MX2019001930A - Ensayo para determinar el potencial para la autoasociacion de una proteina usando espectroscopia de nanoparticulas de autointeraccion dependiente de la concentracion. - Google Patents
Ensayo para determinar el potencial para la autoasociacion de una proteina usando espectroscopia de nanoparticulas de autointeraccion dependiente de la concentracion.Info
- Publication number
- MX2019001930A MX2019001930A MX2019001930A MX2019001930A MX2019001930A MX 2019001930 A MX2019001930 A MX 2019001930A MX 2019001930 A MX2019001930 A MX 2019001930A MX 2019001930 A MX2019001930 A MX 2019001930A MX 2019001930 A MX2019001930 A MX 2019001930A
- Authority
- MX
- Mexico
- Prior art keywords
- self
- protein
- association
- potential
- test
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
- G01N21/77—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
- G01N33/587—Nanoparticles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N2021/258—Surface plasmon spectroscopy, e.g. micro- or nanoparticles in suspension
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plasma & Fusion (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicinal Preparation (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
- Analysing Materials By The Use Of Radiation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662376788P | 2016-08-18 | 2016-08-18 | |
| PCT/US2017/047630 WO2018035470A1 (en) | 2016-08-18 | 2017-08-18 | Assay for determining potential to self-association of a protein using concentration-dependent self-interaction nanoparticle spectroscopy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019001930A true MX2019001930A (es) | 2019-07-04 |
Family
ID=59746357
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019001930A MX2019001930A (es) | 2016-08-18 | 2017-08-18 | Ensayo para determinar el potencial para la autoasociacion de una proteina usando espectroscopia de nanoparticulas de autointeraccion dependiente de la concentracion. |
| MX2023013583A MX2023013583A (es) | 2016-08-18 | 2019-02-15 | Ensayo para determinar el potencial para la autoasociacion de una proteina usando espectroscopia de nanoparticulas de autointeraccion dependiente de la concentracion. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023013583A MX2023013583A (es) | 2016-08-18 | 2019-02-15 | Ensayo para determinar el potencial para la autoasociacion de una proteina usando espectroscopia de nanoparticulas de autointeraccion dependiente de la concentracion. |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US11428695B2 (https=) |
| EP (2) | EP3500856B1 (https=) |
| JP (3) | JP6959327B2 (https=) |
| KR (3) | KR102717462B1 (https=) |
| CN (2) | CN115468919A (https=) |
| AU (2) | AU2017313150B2 (https=) |
| BR (1) | BR112019003175A2 (https=) |
| CA (3) | CA3254461A1 (https=) |
| DK (2) | DK3500856T3 (https=) |
| EA (1) | EA201990316A1 (https=) |
| ES (2) | ES2837093T3 (https=) |
| FI (1) | FI3761035T3 (https=) |
| HU (2) | HUE052805T2 (https=) |
| IL (2) | IL264640B2 (https=) |
| MX (2) | MX2019001930A (https=) |
| PL (2) | PL3500856T3 (https=) |
| SG (1) | SG11201900895QA (https=) |
| WO (1) | WO2018035470A1 (https=) |
| ZA (1) | ZA201901035B (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11428695B2 (en) | 2016-08-18 | 2022-08-30 | Regeneron Pharmaceuticals, Inc. | Concentration-dependent self-interaction assay |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11103552B2 (en) | 2018-05-10 | 2021-08-31 | Regeneron Pharmaceuticals, Inc. | High concentration VEGF receptor fusion protein containing formulations |
| CN113588582B (zh) * | 2020-04-30 | 2024-05-14 | 上海药明生物技术有限公司 | 蛋白质样品浓度测定方式选择法及测定方法 |
| WO2023095154A1 (en) * | 2021-11-24 | 2023-06-01 | Sensoville Biotech Pvt Ltd | Method for determining changes in a protein's structure |
| WO2023141319A1 (en) * | 2022-01-24 | 2023-07-27 | Amgen Inc. | Methods for detecting antibody self-association |
| CN119832975A (zh) * | 2024-12-24 | 2025-04-15 | 上海药明生物技术有限公司 | 一种蛋白质共处方制剂的稳定性预测方法 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US771997A (en) | 1903-11-21 | 1904-10-11 | Alfred Palm | Lathe attachment. |
| US4254102A (en) * | 1975-09-08 | 1981-03-03 | Plough, Inc. | Substantive PABA compositions |
| US4080264A (en) | 1976-03-01 | 1978-03-21 | Massachusetts Institute Of Technology | Immunoassay by light scattering spectroscopy |
| US6927044B2 (en) | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US20050214356A1 (en) * | 2004-03-24 | 2005-09-29 | Joyce Timothy H | Self assembling activation agents targeted using active drug release |
| US20050221507A1 (en) * | 2004-03-30 | 2005-10-06 | Intel Corporation | Method to detect molecular binding by surface-enhanced Raman spectroscopy |
| US7514938B2 (en) | 2004-05-11 | 2009-04-07 | Board Of Regents Of The University And College System Of Nevada, On Behalf Of The University Of Nevada, Reno | Dielectric relaxation spectroscopy apparatus and methods of use |
| TW200621282A (en) | 2004-08-13 | 2006-07-01 | Wyeth Corp | Stabilizing formulations |
| CN101238141B (zh) * | 2005-05-02 | 2016-10-12 | 巴斯福股份公司 | 灵敏检测分析物的新标记策略 |
| WO2007121363A2 (en) | 2006-04-13 | 2007-10-25 | Mississippi State University | An optical apparatus for simultaneously measuring the scattering and concentration signals of macromolecules in a flow cell |
| EP2076287A2 (en) | 2006-10-12 | 2009-07-08 | Wyeth | Methods and compositions with reduced opalescence |
| GB0621050D0 (en) * | 2006-10-23 | 2006-11-29 | Univ Strathclyde | Functionalised polymers for labelling metal surfaces |
| WO2008151219A1 (en) | 2007-06-04 | 2008-12-11 | Regeneron Pharmaceuticals, Inc. | Enhanced expression and stability regions |
| US20090104114A1 (en) * | 2007-09-21 | 2009-04-23 | Cytimmune Sciences, Inc. | Nanotherapeutic Colloidal Metal Compositions and Methods |
| US20110305765A1 (en) * | 2008-11-21 | 2011-12-15 | Board Of Regents, The University Of Texas System | Preparation and methodology of silk fibroin nanoparticles |
| US20140024024A1 (en) * | 2012-07-17 | 2014-01-23 | General Electric Company | Methods of detecting dna, rna and protein in biological samples |
| WO2014192937A1 (ja) * | 2013-05-30 | 2014-12-04 | 公立大学法人大阪府立大学 | 被検出物質の検出装置および方法 |
| IL312865B2 (en) * | 2013-09-11 | 2025-06-01 | Eagle Biologics Inc | Liquid protein formulations containing viscosity-lowering agents |
| EP2902503A1 (en) * | 2014-01-31 | 2015-08-05 | Fundación Imdea Nanociencia | Functionalized metal nanoparticles and uses thereof for detecting nucleic acids |
| WO2015196091A1 (en) * | 2014-06-20 | 2015-12-23 | Reform Biologics, Llc | Viscosity-reducing excipient compounds for protein formulations |
| CN104062287B (zh) | 2014-07-01 | 2017-08-08 | 福建工程学院 | 一种基于纳米金催化的化学发光分析检测铁蛋白的方法 |
| MA40861A (fr) | 2014-10-31 | 2017-09-05 | Biogen Ma Inc | Anticorps anti-glycoprotéines iib/iiia |
| WO2016115475A1 (en) * | 2015-01-18 | 2016-07-21 | Biogen Ma Inc. | Anti-cd40 antibody formulations |
| DK3500856T3 (da) | 2016-08-18 | 2020-12-14 | Regeneron Pharma | Assay til bestemmelse af et proteins potentiale for at selvassociere ved hjælp af koncentrationsafhængig selvinteraktionsnanopartikelspektroskopi |
-
2017
- 2017-08-18 DK DK17761159.7T patent/DK3500856T3/da active
- 2017-08-18 HU HUE17761159A patent/HUE052805T2/hu unknown
- 2017-08-18 BR BR112019003175-8A patent/BR112019003175A2/pt not_active Application Discontinuation
- 2017-08-18 KR KR1020237016537A patent/KR102717462B1/ko active Active
- 2017-08-18 CA CA3254461A patent/CA3254461A1/en active Pending
- 2017-08-18 CN CN202211108451.8A patent/CN115468919A/zh active Pending
- 2017-08-18 CA CA3254460A patent/CA3254460A1/en active Pending
- 2017-08-18 AU AU2017313150A patent/AU2017313150B2/en active Active
- 2017-08-18 HU HUE20191942A patent/HUE066064T2/hu unknown
- 2017-08-18 CN CN201780050825.6A patent/CN109661577B/zh active Active
- 2017-08-18 IL IL264640A patent/IL264640B2/en unknown
- 2017-08-18 DK DK20191942.0T patent/DK3761035T3/da active
- 2017-08-18 SG SG11201900895QA patent/SG11201900895QA/en unknown
- 2017-08-18 JP JP2019508809A patent/JP6959327B2/ja active Active
- 2017-08-18 EP EP17761159.7A patent/EP3500856B1/en active Active
- 2017-08-18 EA EA201990316A patent/EA201990316A1/ru unknown
- 2017-08-18 IL IL307435A patent/IL307435A/en unknown
- 2017-08-18 PL PL17761159T patent/PL3500856T3/pl unknown
- 2017-08-18 US US16/326,238 patent/US11428695B2/en active Active
- 2017-08-18 WO PCT/US2017/047630 patent/WO2018035470A1/en not_active Ceased
- 2017-08-18 PL PL20191942.0T patent/PL3761035T3/pl unknown
- 2017-08-18 FI FIEP20191942.0T patent/FI3761035T3/fi active
- 2017-08-18 ES ES17761159T patent/ES2837093T3/es active Active
- 2017-08-18 EP EP20191942.0A patent/EP3761035B1/en active Active
- 2017-08-18 MX MX2019001930A patent/MX2019001930A/es unknown
- 2017-08-18 KR KR1020227030436A patent/KR102534506B1/ko active Active
- 2017-08-18 KR KR1020197006376A patent/KR102441221B1/ko active Active
- 2017-08-18 CA CA3032361A patent/CA3032361C/en active Active
- 2017-08-18 ES ES20191942T patent/ES2974961T3/es active Active
-
2019
- 2019-02-15 MX MX2023013583A patent/MX2023013583A/es unknown
- 2019-02-18 ZA ZA2019/01035A patent/ZA201901035B/en unknown
-
2021
- 2021-10-07 JP JP2021165510A patent/JP7321227B2/ja active Active
-
2022
- 2022-07-20 US US17/868,983 patent/US11988668B2/en active Active
-
2023
- 2023-07-25 JP JP2023120438A patent/JP2023139189A/ja active Pending
- 2023-12-04 AU AU2023274236A patent/AU2023274236A1/en not_active Abandoned
-
2024
- 2024-04-16 US US18/637,055 patent/US20240280582A1/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11428695B2 (en) | 2016-08-18 | 2022-08-30 | Regeneron Pharmaceuticals, Inc. | Concentration-dependent self-interaction assay |
| US11988668B2 (en) | 2016-08-18 | 2024-05-21 | Regeneron Pharmaceuticals, Inc. | Concentration-dependent self-interaction assay |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019001930A (es) | Ensayo para determinar el potencial para la autoasociacion de una proteina usando espectroscopia de nanoparticulas de autointeraccion dependiente de la concentracion. | |
| CY1126062T1 (el) | Σταθερη φαρμακοτεχνικη μορφη anti-ifnar1 | |
| CY1125392T1 (el) | Συνθεσεις και μεθοδοι γλυζυλιωσης πρωτεϊνων | |
| BR112015024553A2 (pt) | anticorpo multiespecífico, anticorpo isolado, ácido nucleico isolado, célula hospedeira, método de produção de anticorpo, imunoconjugado, formulação farmacêutica, uso de anticorpo e método de tratamento de indivíduos com distúrbio | |
| CY1125697T1 (el) | Σταθερες, υδατικες φαρμακοτεχνικες μορφες αντισωματων | |
| CO2018005932A2 (es) | Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas | |
| MY198335A (en) | Urinalysis Device and Dry Reagent for Quantitative Urinalysis | |
| WO2014141152A3 (en) | Low concentration antibody formulations | |
| CL2016002116A1 (es) | Anticuerpos anti-fap y métodos de utilización (divisional sol. n°369-13). | |
| GB2569252A (en) | Methods of combining the detection of biomolecules into a single assay using fluorescent in situ sequencing | |
| CL2016002105A1 (es) | Método in vitro para determinar un pronóstico pobre en un paciente que tiene melanoma que comprende: (a) detectar el nivel de expresión de un ligando similar a delta 3 (dll3) en una muestra, donde la detección comprende poner en contacto la muestra con un anticuerpo anti-dll3. | |
| EA201592302A1 (ru) | Способы снижения уровня остаточного холестерина и других фракций липопротеинов путем введения ингибитора пропротеиновой конвертазы субтилизин-кексинового типа 9 (pcsk9) | |
| PE20200479A1 (es) | Ensayos de diagnostico para detectar, cuantificar y/o rastrear microbios y otros analitos | |
| CL2018000232A1 (es) | Mezcla de péptidos (divisional solicitud 201601405) | |
| UY34995A (es) | Formulaciones de anticuerpo y proteína | |
| CL2015000352A1 (es) | Métodos de tratamiento de una tauopatía | |
| BR112017017025A2 (pt) | métodos e composições para analizar componentes celulares | |
| MX2015012437A (es) | Esteroides neuroactivos, composiciones, y usos de los mismos. | |
| BR112017010078A2 (pt) | composições, dispositivos e métodos de teste de sensibilidade de ibs | |
| MX388858B (es) | Reducción de la viscosidad de formulaciones farmacéuticas | |
| BR112019006853A2 (pt) | composição farmacêutica líquida | |
| BR112016014756A8 (pt) | formulação de selante compreendendo fibrinogênio e zimogênios, seu método de fabricação, recipiente e uso | |
| BR112015013540A2 (pt) | formulação em solução, métodos para tratar uma doença autoimune, doença inflamatória ou distúrbio proliferativo e psoríase, e, uso de uma formulação em solução | |
| BR112016028838A2 (pt) | anticorpos, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, métodos de detecção de lgr5 humano em uma amostra biológica, de detecção de um câncer, de identificação de um paciente com câncer, de seleção de um paciente com câncer para tratamento com um imunoconjugado e de tratamento de um paciente com câncer | |
| BR112014026440A2 (pt) | assays, methods and apparatus for assessing rna disruption |